Isomorphic Labs and MSD: A Revolutionary Partnership in Drug Discovery
On November 19, 2026, Isomorphic Labs, a leader in artificial intelligence-driven drug design, announced a strategic research collaboration with MSD (Merck & Co., Inc.) based in Rahway, New Jersey. This partnership uniquely blends Isomorphic Labs' advanced AI capabilities in drug discovery with MSD’s extensive data resources and expertise in therapeutic research, specifically targeting an important oncology-related target.
Isomorphic Labs will utilize its proprietary drug design engine, IsoDDE, to predict therapeutic candidates through advanced in silico simulations. By integrating high-quality datasets provided by MSD into their innovative framework, they aim to design molecular structures that have the potential to become viable therapeutic agents. On the other hand, MSD will take charge of the clinical development, manufacturing, and eventual commercialization of any products that emerge from this collaboration.
Under the terms of their agreement, Isomorphic Labs will receive an initial payment from MSD. The partnership also includes potential milestone payments contingent upon achieving specific research, development, regulatory, and commercialization goals, alongside tiered royalties based on net sales. Additionally, Isomorphic Labs may opt to co-finance development activities to secure higher royalty rates on sales.
Sarah Skerratt, Research Director at Isomorphic Labs, emphasized the significance of this partnership, stating, "Through this collaboration with MSD, we will apply our world-leading drug design engine to make significant advancements in discovering new treatments. By leveraging the generative and predictive capabilities of IsoDDE to tackle this complex program, the collaboration underscores our shared commitment to innovation for patients with unmet medical needs."
George Addona, Senior Vice President and Head of Discovery, Preclinical Development, and Translational Medicine at MSD Research Laboratories, also highlighted the need for a close synergy between experimental laboratory work and computational modeling. He noted that by combining MSD's robust internal data capabilities and research expertise with Isomorphic Labs' advanced computational modeling, they aim to identify new candidates more quickly and effectively than ever before.
This partnership illustrates the transformative power of integrating advanced AI, unique datasets, and a strong bio-pharmaceutical leadership track record. It aims to accelerate the development of therapeutic candidates that target complex biological challenges with unprecedented speed and accuracy.
About Isomorphic Labs
Founded in 2021, Isomorphic Labs seeks to revolutionize drug discovery through the power of artificial intelligence. The company operates under the guidance of CEO Sir Demis Hassabis and President Max Jaderberg, and has developed a globally recognized drug design engine, IsoDDE, which is modality-agnostic and built on foundational AI models. Their computational drug design system is known for providing the predictive fidelity necessary to explore novel biological systems with unmatched precision.
Isomorphic Labs continuously innovates in model architecture and develops cutting-edge capabilities to drive drug design forward. Based in London, with additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland, the company maintains a diverse and ambitious portfolio of drug design through both collaborative and proprietary programs. For further information, visit
www.isomorphiclabs.com or follow them on LinkedIn and X.
About MSD
MSD, known as Merck & Co., Inc. in the United States and Canada, unites employees under a common purpose: to leverage cutting-edge science for improving and saving lives globally. For over 130 years, they have provided hope to humanity through the development of essential medications and vaccines. MSD strives to be the world’s leading research-focused biopharmaceutical company, constantly at the forefront of innovative health solutions that promote disease prevention and treatment for both humans and animals. They pride themselves on a diverse and inclusive global workforce, operating responsibly every day to contribute to a safe, sustainable, and healthy future for all communities. For more information, visit
www.msd.com and connect with them on X, LinkedIn, and YouTube.